




February 2006 Update

NAV/share (06/02/06): EUR 131.08

ISIN code: LU0141953439

website: www.citadelfund.com



Citadel Value Fund Performance
(as of February 6th, 2006)

	Since inception (11/02/02)	3 year	1 year	2006* YTD
Citadel Value Fund	31.1%	67.3%	14.9%	4.7%
MSCI World Index	7.6%	65.6%	23.8%	1.7%

note: MSCI World Index is based on total returns in Euro's

* annual returns are based on estimated NAV as of Dec. 31, 2002/03/04 & 05

source: European Fund Administration, MSCI

Top 10 holdings

Heineken Holding NV	6.1%
Lambert Howarth PLC	6.1%
Telegraaf Media Groep NV	5.8%
Wegener NV	5.0%
Bristol-Myers Squibb Co.	5.0%
Ultraframe PLC	4.4%
Batenburg Beheer NV	4.4%
Nedschroef Holding NV	4.1%
Zwack Unicum Rt	4.0%
Wolters Kluwer NV	4.0%

COMMENTARY

Citadel got off to a good start in 2006 with the NAV rising by 4.7% since December 31st. Since inception – a period which is now almost exactly four years – the Fund is up by 31.1%. During the same period global equities as represented by the MSCI World Index rose by 7.6%. Interestingly, a number of the worst performers in 2005Q4 put in the best performance since the start of the year.

We are increasingly optimistic about the fundamentals underlying a number of the Fund's newspaper holdings. **VLT** in Sweden released excellent results as ad revenues climbed and cost savings boosted the bottom line. **Wegener's** stock rose sharply due to persisting rumours of private equity interest. Whether there is fire behind the smoke remains to be seen; however, its prospects look good. In its home market of Holland, the first signs of an advertising recovery are visible, and the company is taking an axe to its costs. **Merck** and **Bristol-Myers Squibb** both presented better than expected 2005 results and some welcome news on new product approvals and submissions. Bristol faces a critical patent case in April and Merck continues its legal **Vioxx** marathon. Their product pipelines are better than is generally accepted and both are making changes to improve R&D productivity and cut costs. After a sharp run-up we decided to sell the Fund's shares in **Merck KGaA** as they approached our estimate of intrinsic value. This was the first holding in Citadel's portfolio. Despite some setbacks – such as an inane decision to issue 10% new shares at close to an historic low – the company's financial performance more than met our expectations. The stock eventually followed, and delivered a return including dividends of 144%.

IMPORTANT: An investment in the Fund carries with it a degree of risk. The value of your investment may go down as well as up, and you could lose money on your investment. Past performance provides no guarantee for the future. Investors should read the Fund's prospectus before deciding whether to invest. The opinions and commentary expressed herein should in no way be construed as personal investment advice, they are intended solely to illustrate the Fund's investment strategy and performance.